Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06784947 · ClinicalTrials.gov registry record · Phase 2
Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer
A Phase 2 study of Metastatic Colorectal Cancer (CRC) and Colorectal Cancer Stage IV, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT06784947: Active Phase 2 study of Metastatic Colorectal Cancer (CRC) and Colorectal Cancer Stage IV, sponsored by University of Colorado, Denver.
NCT06784947 is a Phase 2 study of Metastatic Colorectal Cancer (CRC) and Colorectal Cancer Stage IV that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 13 participants, below the 225-participant average among 5 other Metastatic Colorectal Cancer (CRC) trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06784947, a Phase 2 study of Metastatic Colorectal Cancer (CRC) and Colorectal Cancer Stage IV, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to learn if a new combination treatment is effective for patients with microsatellite stable, advanced colorectal cancer. The study treatment combines 3 drugs: atezolizumab, bevacizumab, and tiragolumab. The main questions the study aims to answer are: 1. Does the study treatment effectively treat colorectal cancer? 2. Is the study treatment safe for patients with colorectal cancer? 3. How does the study treatment effect the immune system in patients with colorectal cancer? Participants in this study will receive the study treatment and undergo checkups, laboratory tests, and imaging tests for monitoring. Some participants will also undergo tumor biopsies.
Primary Outcome
The primary outcome of this trial is objective response rate (ORR), defined as the proportion of patients who achieve a complete or partial response to treatment according to RECIST v1.1 criteria.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Tiragolumab
- PROCEDURE Pre-Treatment Biopsy
- PROCEDURE On-Treatment Biopsy
Study Locations (1)
Colorado
- Universtiy of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2025-03-25 |
| Est. Completion | 2028-05 |
| Phase | Phase 2 |
What the registry record for NCT06784947 still lists
NCT06784947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 225-participant average among 5 other Metastatic Colorectal Cancer (CRC) trials with a reported enrollment target (94% lower).
The record links to 3 conditions, with Metastatic Colorectal Cancer (CRC) appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT06784947 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06784947 about?
NCT06784947 is a clinical study titled "Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer". The goal of this study is to learn if a new combination treatment is effective for patients with microsatellite stable, advanced colorectal cancer. The study treatment combines 3 drugs: atezolizumab, bevacizumab, and tiragolumab. The main questions the study aims to answer are: 1. Does the study tr...
What is the current status of trial NCT06784947?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2025-03-25. Estimated completion is 2028-05.
What conditions does trial NCT06784947 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV, Microsatellite Stable (MSS) Colorectal Cancer (CRC).
What interventions are being tested in trial NCT06784947?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Tiragolumab (DRUG), Pre-Treatment Biopsy (PROCEDURE), On-Treatment Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT06784947?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06784947 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer (CRC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
RECRUITING · Phase 3
-
Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy
RECRUITING · Early Phase 1
-
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI